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Abstract
Background: Altered DNA methylation of imprinted genes has been implicated in a range of cancers. Imprinting is
established early in development, and some are maintained throughout the life course in multiple tissues,
providing a plausible mechanism linking known early life factors to cancer risk. This study investigated methylation
status of seven imprinted differentially methylated regions—PLAGL1/ZAC1, H19-ICR1, IGF2-DMR2, KvDMR-ICR2, RB1,
SNRPN-DMR1 and PEG3—in blood samples from 189 women with the most common type of invasive breast cancer
(invasive ductal carcinoma—IDC), 41 women with in situ breast cancer (ductal carcinoma in situ—DCIS) and 363
matched disease-free controls.
Results: There was no evidence that imprinted gene methylation levels varied with age (between 25 and 87 years
old), weight or height. Higher PEG3 methylation was associated with an elevated risk of IDC (odds ratio (OR) 1.065;
95 % confidence interval (CI) 1.002, 1.132; p = 0.042) and DCIS (OR 1.139; 95 % CI 1.027, 1.263; p = 0.013). The effect
was stronger when in situ and invasive breast cancer were combined (OR 1.079; 95 % CI 1.020, 1.142; p = 0.008).
DCIS breast cancer risk increased with higher KvDMR-ICR2 methylation (OR 1.395; 95 % CI 1.190, 1.635; p < 0.001)
and lower PLAGL1/ZAC1 methylation (OR 0.905; 95 % CI 0.833, 0.982; p = 0.017). In a combined model, only KvDMR-ICR2
methylation remained significantly associated.
Conclusions: These findings may help to improve our understanding of the aetiology of breast cancer and the
importance of early life factors in particular. Imprinting methylation status also has the potential to contribute to the
development of improved screening and treatment strategies for women with, or at risk of, breast cancer.
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Background
Breast cancer is the most common type of cancer in
women in the UK, with a lifetime risk of one in eight
[1]. Improvements in detection and treatment have in-
creased survival rates, and currently, 85 % of women
survive more than 5 years after diagnosis [1]. However,
it is still the most common cause of cancer death in the
world for women, with incidence markedly increasing
[2]. The heritability of breast cancer is estimated at
about 30 % but known genetic risk variants (e.g. BRCA1,
BRCA2, TP53 and PTEN) only account for around 5–
10 % of all cases [3, 4]. Non-genetic factors such as
obesity, alcohol consumption, diet, birth weight and
exposure to oestrogen have all been linked to breast can-
cer risk, but the mechanisms underpinning these associ-
ations have yet to be identified [5, 6].
A common observation in human breast cancers, and
many other tumour types, is epigenetic change, includ-
ing altered methylation of DNA. There is an increasing
interest in the role of epigenetics as a potential mechan-
ism linking environmental exposures to cancer risk and
as a non-genetic explanation for cancer heritability [7].
Aberrant DNA methylation has been reported in breast
tumours for a number of genes involved in apoptosis, cell
cycle control and DNA repair [8]. One class of epigenetic
mark with particular relevance to cancer is imprinting; the
epigenetic marking of genes in a parent-of-origin specific
manner within the germ cells [9]. There is intra-individual
variation of imprinting DNA methylation, and the early
factors that influence this variability and the potential
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effects on later life cancer risk are of particular interest
[10–12]. Once set, many germ line imprints are main-
tained in a wide range of adult somatic tissues across the
life course [13, 14]. A number of imprinted genes are
known tumour suppressors or oncogenes, and loss of im-
printing is a hallmark of many cancers [8, 15, 16]. Interest-
ingly, relaxation or loss of imprinting in apparently normal
tissue of individuals with cancer or those at increased risk
of the disease has been observed in normal colonic epithe-
lium and normal breast tissue [17, 18]. These observations
are relevant to the concept of field cancerisation—changes
in normal tissue that predispose to the development of can-
cer—and the possible role of early factors in programming
breast cancer susceptibility [10, 19]. The soma-wide nature
of imprinting also makes this signal useful to consider as a
potential biomarker of breast cancer.
DNA methylation changes in blood have been reported
in breast cancer [20–22] and in relation to the pathological
characteristics of breast cancer including histological type,
tumour size and receptor status [23, 24]. Some apparent
changes in blood DNA methylation in disease states could
simply reflect changes in blood cell types [25, 26], and one
advantage of studying imprinted genes is that they are
unaffected by cellular heterogeneity [27].
The present study was undertaken to determine whether
breast cancer risk was associated with altered DNA methy-
lation of selected imprinted differentially methylated
regions (DMRs) in non-tumour tissue (blood). Six germ
line DMRs, identified to regulate the associated imprinted
gene regions, were chosen for pyrosequencing analysis:
PLAGL1/ZAC1 [OMIM 603044], H19 [OMIM 103280],
KvDMR [OMIM 604115], RB1 [OMIM 614041], SNRPN
[OMIM 18227] and PEG3 [OMIM 601483]. A somatic
region (DMR2) linked with IGF2 [OMIM 147470] was also
selected for analysis. This DMR interacts with H19 on the
methylated paternal allele [28], has been linked with IGF2
expression [29] and has been associated with nutritional in
utero exposures [12, 30] and birth outcomes [31]. Methyla-
tion status was determined in blood samples collected
at diagnosis and prior to treatment from women with
the most common type of invasive breast cancer (inva-
sive ductal carcinoma—IDC), the most common type
of in situ cancer (ductal carcinoma in situ—DCIS) and
disease-free controls. Subjects were matched for age,
height, weight, body mass index (BMI) and menopausal
status. A growing number of studies investigating
tumour and non-tumour DNA methylation levels use
array technologies such as the Illumina Infinium®
HumanMethylation450 BeadChip [32] but this technol-
ogy provides poor coverage of the imprinted regions of
interest here. We investigated DNA methylation of
these seven imprinted DMRs by pyrosequencing
analysis.
Results
The mean methylation levels for all imprinted DMRs are
summarised in Table 1. These are in line with the predicted
50 % DNA methylation levels for imprinted genes, 100 %
methylation on one allele and 0 % on the other. The mean
RB1 methylation was relatively high (68.61 %; SD = 4.65),
but within the range of 33–70 % methylation, commonly
reported for imprinted regions [33]. The somatic imprinted
region IGF2-DMR2 had the highest inter-individual
variability (48.50 %; SD = 5.72). There were no significant
differences in age, height, weight and BMI between the
matched cases and controls (Table 2).
The methylation level for the selected imprinted
DMRs is shown for all of the disease-free women (Fig. 1).
There was no evidence for a change in methylation of
imprinted DMRs with age in this cross-sectional ana-
lysis. Neither were the imprinted DMR methylation
levels significantly linked with weight or BMI of the
disease-free women. Height was associated with RB1
methylation, although this association was relatively
weak (regression coefficient = 0.007; 95 % CI 0.000,
0.014; p = 0.049; r2 = 0.0116).
Increased PEG3 methylation was associated with an el-
evated risk of both IDC (odds ratio = 1.065; 95 % CI
1.002, 1.132; p = 0.042) and DCIS (odds ratio = 1.139;
95 % CI 1.027, 1.263; p = 0.013) compared to the
Table 1 Average methylation levels for imprinted gene DMRs
Cohort Imprinted gene DMRs
Chr. 6 Chr. 11 Chr. 13 Chr. 15 Chr. 19
PLAGL1 H19 IGF2 KvDMR RB1 SNRPN PEG3
Combined 55.78 (4.92) 59.76 (4.19) 48.50 (5.72) 44.28 (2.36) 68.61 (4.65) 43.97 (3.00) 52.30 (2.99)
Disease-free 55.91 (4.92) 59.59 (4.35) 48.15 (5.77) 44.17 (2.34) 68.61 (4.30) 44.03 (3.03) 52.05 (2.93)
DCIS 53.90 (3.60) 59.70 (3.79) 49.52 (5.66) 45.81 (1.99) 68.22 (3.95) 43.62 (3.20) 53.29 (3.61)
IDC 55.92 (5.08) 60.10 (3.97) 48.94 (5.61) 44.13 (2.36) 68.68 (5.38) 43.93 (2.91) 52.57 (2.89)
Average percent methylation (%) reported (and standard deviation). Combined cohort included all disease-free women and breast cancer cases n = 593.
Disease-free women n= 363. DCIS (ductal carcinoma in situ) n = 41. IDC (invasive ductal carcinoma) n = 189
PLAGL1 pleomorphic adenoma gene like 1, H19 H19, imprinted maternally expressed non-coding transcript-imprint control region 1, IGF2 insulin-like growth
factor 2. KvDMR 11p15 region imprint control region 2, RB1 retinoblastoma 1. SNRPN small nuclear ribonucleoprotein polypeptide N, PEG3 paternally expressed
gene 3. DMR: differentially methylated region. Chr: chromosome
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controls (Table 3). This effect was more significant when
DCIS and IDC were combined (odds ratio = 1.079; 95 %
CI 1.020, 1.142; p = 0.008). There was no significant dif-
ference in PEG3 methylation between the IDC and DCIS
cases. The distribution of PEG3 methylation according
to disease status is shown in Fig. 2. IGF2 methylation
was also higher in combined IDC and DCIS cases com-
pared to controls but this effect did not achieve statis-
tical significance (p = 0.068).
Two other DMRs exhibited differences in methylation
in the DCIS cases compared to the controls (Table 3).
Increased KvDMR-ICR2 methylation was associated with
an elevated risk of DCIS (odds ratio = 1.395; 95 % CI
1.190, 1.635; p < 0.001). Increased KvDMR-ICR2 methy-
lation was also observed for the DCIS cases compared to
the IDC cases (Odds Ratio = 1.413; 95 % CI 1.168, 1.681;
p < 0.001), confirming this association within DCIS cases
only. Risk of DCIS decreased with increasing PLAGL1/
ZAC1 methylation (odds ratio = 0.905; 95 % CI 0.833,
0.982; p = 0.017) (Table 3). Again, a significant differ-
ence was observed between the DCIS and IDC cases
(odds ratio = 0.904; 95 % CI 0.830, 0.983; p = 0.018),
confirming the effects for PLAGL1/ZAC1 methylation
to be specific for the DCIS cases. Further statistical
analysis showed that PLAGL1/ZAC1 methylation was
inversely correlated with KVDMR-ICR2 (correlation
coefficient = −0.290; p < 0.001). When both PLAGL1/
ZAC1 and KVDMR-ICR2 were included in the same lo-
gistic regression model, only KvDMR-ICR2 remained
significant (data not shown).
An overview of the pathological characteristics of IDC
are summarised in Table 4. Further analysis based on
subsets of the data produced some significant associa-
tions but the numbers in these comparisons were small
and the results are included here primarily as hypothesis
generating for future studies. Decreasing SNRPN methy-
lation was associated with higher IDC histological grade
(grade 3) compared to low histological grade 1 IDC
(odds ratio = 0.808; 95 % CI 0.674, 0.969; p = 0.022) and
combined histological grades 1 and 2 (odds ratio = 0.833;
95 % CI 0.711, 0.976; p = 0.024). Decreasing SNRPN
methylation was also linked to increasing tumour size
(regression coefficient = −0.047; 95 % CI −0.076, −0.019;
p = 0.001). Both of these characteristics are associated
with a poorer prognostic outcome. Higher SNRPN methy-
lation was linked to a ‘good’ Nottingham Prognostic Index
(NPI) prognostic category compared to a ‘moderate’, ‘poor’
or combined ‘moderate’ and ‘poor’ category (data not
shown). The NPI category is partly determined by IDC
grade and tumour size. Increased KvDMR-ICR2 methyla-
tion appeared to be associated with oestrogen receptor (ER)
positive status, after adjustment for breast cancer type
(odds ratio = 1.197; 95 % CI 1.032, 1.389; p = 0.018). No
other pathological features (including progesterone
Table 2 Subject characteristics by disease status
Characteristic Controls (n = 363) Cases (n = 230) p value
Age (years) 56 (11) 56 (11) 0.499
Height (m) 1.615 (0.07) 1.615 (0.06) 0.974
Weight (kg) 70.91 (14.25) 70.75 (13.50) 0.889
BMI (kg/m2) 27.20 (5.21) 27.14 (4.97) 0.902
Mean values with standard deviations (sd) shown in brackets. p values
calculated using a two-sample Student’s t test
Fig. 1 Imprinted gene methylation and age in disease-free women.
Average methylation (%) within imprinted genes PLAGL1/ZAC1, RB1,
H19-ICR1, SNRPN-DMR1, IGF2-DMR2, PEG3 and KvDMR-ICR2 according
to age for all disease-free samples. Linear regression analysis fit
shown with a solid line and with 95 % CI shown with a dashed line.
Average methylation levels are shown by an open circle. None of the
associations were statistically significant. PLAGL1/ZAC1 pleomorphic
adenoma gene like 1, RB1 retinoblastoma 1, H19 H19, imprinted
maternally expressed non-coding transcript-imprint control region 1,
SNRPN small nuclear ribonucleoprotein polypeptide N, IGF2 insulin-
like growth factor 2, PEG3 paternally expressed gene 3, KvDMR
11p15 region imprint control region 2, CI confidence intervals
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Table 3 Logistic regression analysis of the effect of methylation level of imprinted gene DMRs on disease risk
Imprinted gene DMRs
Chr. 6 Chr. 11 Chr. 13 Chr. 15 Chr. 19
PLAGL1/ZAC1 H19-ICR1 IGF2-DMR2 KvDMR-ICR2 RB1 SNRPN-DMR1 PEG3
All Cases vs. Controls
0.987 [0.953,1.022]
p = 0.462
1.026 [0.986,1.068]
p = 0.210
1.028 [0.998,1.059] p = 0.068 1.049 [0.976,1.128] p = 0.193 1.001 [0.965,1.038] p = 0.947 0.985 [0.930,1.043] p = 0.601 1.079** [1.020,1.142] p = 0.008
IDC vs. Controls
1.002 [0.966,1.039]
p = 0.932
1.030 [0.987,1.074]
p = 0.171
1.025 [0.994,1.057] p = 0.123 0.993 [0.920,1.072] p = 0.860 1.006 [0.967,1.046] p = 0.772 0.991 [0.932,1.054] p = 0.932 1.065* [1.002,1.132] p = 0.042
DCIS vs. Controls
0.905* [0.833,0.982]
p = 0.017
1.007 [0.932,1.088]
p = 0.862
1.039 [0.984,1.099] p = 0.170 1.395*** [1.190,1.635] p < 0.001 0.976 [0.904,1.053] p = 0.530 0.954 [0.851,1.068] p = 0.412 1.139* [1.027,1.263] p = 0.013
DCIS vs. IDC
0.904* [0.830,0.983]
p = 0.018
0.967 [0.882,1.060]
p = 0.474
1.021 [0.961,1.084] p = 0.509 1.413*** [1.168,1.681] p < 0.001 0.984 [0.924,1.048] p = 0.613 0.967 [0.856,1.092] p = 0.586 1.084 [0.971,1.270] p = 0.150
Logistic regression analysis, reporting odds ratios [95 % confidence intervals]. *p < 0.05, **p < 0.01, ***p < 0.001. Analysis adjusted for menopausal status, age and weight. All cases cohort describes combined IDC
(invasive ductal carcinoma) and DCIS (ductal carcinoma in-situ) cases. DMR: differentially methylated region. Chr: chromosome. PLAGL1/ZAC1: Pleomorphic adenoma gene like 1. H19: H19, imprinted maternally
expressed non-coding transcript-Imprint control region 1. IGF2: Insulin-like growth factor 2. KvDMR: 11p15 region imprint control region 2. RB1: Retinoblastoma 1. SNRPN: Small nuclear Ribonucleoprotein polypeptide
N. PEG3: Paternally expressed gene 3
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receptor—PR or human epidermal growth factor
2—HER2 status) were significantly associated with
methylation levels.
Discussion
Cross-sectional analysis of all of the imprinted regions
(PLAGL1/ZAC1, H19-ICR1, IGF2-DMR2, KvDMR-ICR2,
RB1, SNRPN-DMR1 and PEG3) in the disease-free group
indicated no change with age (between the age of 25 and
87 years). This reinforces the soma-wide nature of im-
printing as blood cell type composition alters with age
[34] which subsequently can influence methylation
levels. These results support the view that imprinted re-
gions are an attractive potential biomarker for examining
breast cancer disease risk and progression, due to the
stability of these throughout life [35].
Increased PEG3 methylation was associated with an el-
evated risk of both IDC and DCIS compared to the con-
trols, and the level of significance was greater when the
two types of cancer were combined. The findings for
PEG3 in non-tumour tissue within this study mirror
those previously reported in tumour samples: increased
methylation of PEG3 has been observed in tumour tissue
of invasive breast and ovarian cancers [36], as well as in-
vasive cervical cancer [37]. Studies have confirmed cor-
relation of PEG3 methylation between multiple tissue
types, including blood and normal breast tissue [38] and
that cancerous breast tumours have increased methyla-
tion compared to benign breast tumours [39]. PEG3 en-
codes a Kruppel-type zinc-finger protein which regulates
the tumour necrosis factor (TNF) response, of which
dysregulation is commonly implicated in cancer [OMIM
601483]. Aberrant PEG3 methylation in blood samples
of women with breast cancer has recently been reported
[39] but this analysis only highlighted the frequency of
extreme outliers for PEG3 methylation, rather than the
more subtle changes in average methylation reported
here. The same study also reported differential outlier
frequency of IGF2-DMR2 in blood samples [39]. Average
IGF2-DMR2 methylation was also increased in com-
bined cases compared to controls in the study described
here, but this effect only approached statistical signifi-
cance. There are also reports of altered IGF2 methyla-
tion in breast tumours [40].
Cancer marker studies suggest a common origin and
development pathway of the two main types of breast
cancer, IDC and DCIS. Reports have identified that low-
grade DCIS can transition to low-grade IDC and high-
grade DCIS to high-grade IDC [41, 42]. The fact that
Table 4 Pathological characteristics of IDC cases, according to
menopausal status
Characteristic All cases
(n = 189)
Pre-menopausal
(n = 66)
Post-menopausal
(n = 123)
Grade
Grade 1 23 (12.2 %) 6 (9 %) 17 (13.8 %)
Grade 2 84 (44.4 %) 30 (45.5 %) 54 (43.9 %)
Grade 3 81 (42.9 %) 30 (45.5 %) 51 (41.5 %)
Missing info. 1 (0.5 %) – 1 (0.8 %)
Lymph node involvement
None 119 (63 %) 38 (57.6 %) 81 (65.9 %)
Axillary lymph
nodes
69 (36.5 %) 28 (42.4 %) 41 (33.3 %)
Missing info. 1 (0.5 %) – 1 (0.8 %)
Hormone receptor status
ER positive 146
(77.2 %)
54 (81.8 %) 92 (74.8 %)
ER negative 43 (22.8 %) 12 (18.2 %) 31 (25.2 %)
PR positive 145
(76.7 %)
53 (80.3 %) 92 (74.8 %)
PR negative 44 (23.3 %) 13 (19.7 %) 31 (25.2 %)
HER2 receptor status
Positive 22 (11.6 %) 11 (16.7 %) 11 (9 %)
Negative 164
(86.8 %)
54 (81.8 %) 110 (89.4 %)
Missing info. 3 (1.6 %) 1 (1.5 %) 2 (1.6 %)
Nottingham prognostic index (NPI)
Good (NPI ≤ 3.4) 71 (37.6 %) 20 (30.3 %) 51 (41.5 %)
Moderate
(NPI 3.41–5.4)
74 (39.1 %) 32 (48.5 %) 42 (34.2 %)
Poor (NPI > 5.41) 35 (18.5 %) 9 (13.6 %) 26 (21.1 %)
Missing info. 9 (4.8 %) 5 (7.6 %) 4 (3.2 %)
Participant numbers for pathological characteristics of IDC (invasive ductal
carcinoma) patients overall and according to menopausal status (and
percent—% of each characteristic)
ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal
growth receptor 2
Fig. 2 Distribution of average PEG3 methylation levels. The distribution
of the average PEG3 methylation levels (percent—%) are presented for
each participant cohort: disease-free women and breast cancer cases.
Breast cancer cases include IDC and DCIS patients. Each participant is
represented by a filled circle. PEG3 paternally expressed gene 3, IDC
invasive ductal carcinoma, DCIS ductal carcinoma in situ
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PEG3 methylation in blood is associated with both DCIS
and IDC separately in this study suggests that this
change could contribute to the common origin and de-
velopment pathway. This information could potentially
contribute to the development of early biomarkers of
breast cancer susceptibility.
Not all women with DCIS will go on to develop inva-
sive breast cancer. The risk of progression is estimated
at 25–50 % for women with low-grade DCIS and 75 %
for women with high-grade DCIS [43]. A recent review
suggested that screening asymptomatic women by mam-
mography resulted in a 20 % reduction in mortality, but
the authors also concluded that around 19 % of diag-
nosed cancers would not have caused a problem if left
untreated [44] and others have suggested that there may
be no survival advantage by breast screening, with the
treatment itself being associated with a significant net
morbidity and mortality [2].
An important clinical challenge is to identify which in-
dividuals can safely be left without treatment [45]. This
study identified DNA methylation changes in blood sam-
ples associated with DCIS only. Increased KvDMR-ICR2
methylation and decreased PLAGL1/ZAC1 methylation
were linked with increasing risk of DCIS compared to
both controls and IDC cases. When both genes were in-
cluded in the same statistical model, only the signifi-
cance for KvDMR-ICR2 methylation remained. Such
findings have the potential to identify individuals with
DCIS who are less likely to progress to invasive breast
cancer. KvDMR-ICR2 regulates the CDKN1C/KCNQ1
domain, including the non-coding antisense KCNQ1OT1
RNA which silences genes on the paternal allele within
this region. Downregulation of CDKN1C (which encodes
p57(KIP2), a negative regulator of cell proliferation—O-
MIM 600856) has been associated with increased metasta-
sis potential and poorer survival for breast cancer [46, 47].
Decreased KCNQ1OT1 methylation has been identified in
tumour development and the imprinting disorder
Beckwith-Wiedemann syndrome which is associated with
tumour predisposition [48]. Altered KvDMR-ICR2 methy-
lation, as observed within this study, may influence breast
cancer risk through an effect on CDKN1C or KCNQ1OT1.
Further work on the links between KvDMR-ICR2 methy-
lation and CDKN1C/KCNQ1OT1 gene expression in can-
cer would be instructive.
Links between imprint signals in normal tissue (such
as blood) and breast cancer risk are particularly relevant
to the concept of ‘field cancerisation’ [19]. This is based
on the idea that widespread changes in normal tissues
precede the development of the disease and increase the
risk of transition to cancer. There is a renewed interest
in this paradigm in relation to epigenetic change, and it
is particularly relevant to imprinting as many germ line
DMRs stably maintain their allele specific methylation
signal in a wide range of adult somatic tissues over the
decades [38, 49, 50]. The soma-wide nature of certain
imprinting signals, such as those studied here, makes
them particularly convenient as biomarkers of breast
cancer risk, type and prognosis since the signal should
be detectable in easily accessible tissues such as blood.
Cell-free circulating DNA (cfDNA) has also been used
in epigenetic studies but these applications tend to be
used for metastatic breast cancer [51]. The correlation
between some imprinting methylation in tumour and
normal tissue means that cfDNA originating from tu-
mours could also potentially be used for this type of
work but there is an extensive epigenetic change in tu-
mours, and cfDNA may not always be relevant to inves-
tigations of cancer-predisposing epigenetic change in
normal tissues.
The differences in imprinting methylation described
here are also relevant to observations linking breast can-
cer susceptibility to early development [10]. A number
of studies and meta-analyses have demonstrated a clear
relationship between birth weight and breast cancer risk,
though there is a debate as to the relative strength of the
association for pre- and post-menopausal breast cancer
[52–56]. The mechanism linking birth weight to breast
cancer risk has not yet been established but imprinting
could provide a plausible link, as one of the key func-
tions of imprinted genes is to regulate foetal growth
[57]. Imprinting methylation has also been linked to
birth weight and health of the new born [31].
Interestingly, there is some evidence that methylation
of imprinted genes may be modifiable by the early envir-
onment such as maternal nutrition before birth. One ex-
ample of this is folic acid. This nutrient is metabolised
through the pathway that provides methyl groups for
DNA methylation, and its use in human pregnancy has
been reported to influence PEG3 and IGF2 methylation
in the offspring [12]. The methylation differences ob-
served here are relatively small in magnitude, and this is
generally the case in population epigenetic studies linking
average methylation levels to phenotypes [10, 31, 58]. Hu-
man epigenetic studies almost universally measure the
average methylation level in a sample of cells, usually
blood or buccal cells, but the distribution and variance of
methylation states may be more important [58]. Many hu-
man diseases have the potential to develop from a subset
of cells, or even one cell as in cancer, and small changes in
the average methylation level could reflect more important
changes in the proportion of cells in high-risk epigenotype
states [56]. From this study, we are not able to suggest a
clear cut-off threshold to identify those individuals who
will definitely develop breast cancer, but the measurement
denotes statistical probability. We suggest that the signifi-
cant regions are worth looking at in more depth to de-
velop a more detailed picture of the methylation signal
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using methods such as next-generation bisulphite sequen-
cing and that they may be used in conjunction with other
risk factors to improve the overall predictive value of these
imprinted gene regions.
Conclusions
Altered DNA methylation has been shown to occur in
tumours, with changes now being identified in non-
tumour tissue such as blood samples. Imprinted gene
methylation is particularly interesting to consider as
these provide potential mechanistic routes to early life
influences and non-genetic heritability of breast cancer.
Using a case-control cohort of almost 600 women, we
have observed increased PEG3 methylation within blood
samples of both invasive and in situ breast cancer cases.
Increased KvDMR-ICR2 methylation was observed in
women with in situ breast cancer compared to both con-
trols and invasive breast cancers. DNA methylation sta-
bility was confirmed for the seven selected imprinted
gene regions within this cohort. The findings set out in
this study suggest potential biomarkers for breast cancer
risk.
Methods
Study population
The study was approved by the North of Scotland Re-
search Ethics Committee (reference number 08/S0801/
17), and all participants gave informed consent. Two
thousand and one hundred seventy-two women were re-
cruited between 2008 and 2013 from the Aberdeen
Breast Clinic with 1168 breast cancer cases and 1004
disease-free controls. The breast cancer patients were
newly diagnosed, with histological confirmation and
without detectable metastatic disease. Blood samples
were taken prior to surgical intervention. The disease-
free women had attended the Aberdeen Breast Clinic
with benign breast changes, none of which significantly
increased their risk of breast cancer. Disease-free status
was confirmed by clinical examination, mammography,
breast ultrasonography and fine needle aspiration cy-
tology where appropriate.
Only European Caucasians were included in the study
and women with known family history of BRCA1/2 mu-
tations and those which have been identified at an in-
creased risk of breast cancer were excluded from the
analysis. The women were identified as having an in-
creased risk of breast cancer if there was known family
history, previous occurrence of atypical ductal hyperpla-
sia, lobular carcinoma in situ or Hodgkin’s disease.
Participant characteristics and pathological informa-
tion including histological type, tumour size, tumour
grade, lymph node status, hormone receptor status and
HER2 expression status were recorded. Nottingham
Prognostic Index was determined using tumour grade,
tumour size and involvement of lymph nodes [59]. In
the initial phase of the study, we included all types of
cancer in the case group and matched an equivalent
numbers of controls. After applying the study exclusion
criteria and removing the more unusual cancer types
(numbers too small for meaningful comparison), the
number of controls (n = 363) exceeded the number of
cases (n = 230) but the groups remained well matched
for the key variables of age, height, weight, body mass
index (BMI) and menopausal status.
Participant characteristics
Age, height, weight and BMI of the participants are
summarised in Table 2. The DCIS cases were classified
as intermediate (27 %), intermediate/high (17 %) or high
(56 %) grade cancers. Information on ER status was
available for 78 % of the DCIS cases (of these, 84 % were
positive and 16 % negative) and PR status for 76 % of
the DCIS cases (of these, 74 % were positive and 26 %
negative). Pathological characteristics for the IDC cases
are summarised in Table 4.
DNA methylation analysis
DNA was extracted from the blood using QIAamp DNA
Mini Blood QIAcube kits (Qiagen, Crawley, UK), auto-
mated on a QIAcube (Qiagen, Crawley, UK). The DNA
was quantified with SYBR® Green on a Rotergene Q
(Qiagen, Crawley, UK) using DNA standards (Life
Technologies, Paisley, UK). The DNA samples were
dispensed into 96-well plates by a QIAgility robotic sys-
tem (Qiagen, Crawley, UK). Matched samples (breast
cancer cases and disease-free controls) were positioned
on the same plate to minimise any potential batch ef-
fects. The samples were treated with sodium bisulphite
using Epitect® 96 Bisulfite kits (Qiagen, Crawley, UK).
Published PCR primers designed for bisulphite-converted
DNA were used for PLAGL1/ZAC1, IGF2-DMR2, SNRPN-
DMR1 and PEG3 assays [60–63]. FASTA sequences were
used to design specific assays using PyroMark Assay Design
Software (version 2.0, Qiagen, Crawley, UK) for the
H19-ICR1, KvDMR-ICR2 and RB1 assays [33]. The
primers were as follows: forward 5′-TGGGGATTTTG
ATGGGGTTA-3′, reverse 5′-biotin-CCTACTCCAAA
CATTATAAAAAAAACTAAC-3′ and sequencing primer
5′-GATGGTTAGGGTGTGTT-3′ for the H19-ICR1
assay; forward 5′-biotin-GGGTGATTATTGGAGTTG
TTGAGGTGAG-3′, reverse 5′-TCCAATCCCAATTC
AACCCACTC-3′ and sequencing primer 5′-CTAA
ACCACCATAAAAACTAT-3′ for the KvDMR-ICR2
assay; forward 5′-biotin-TGGGGTTAGGAGGTGAAA
GTGG-3′, reverse 5′-CATATAAAACAACAACAAAT
CCCTTTCTAC-3′ and sequencing primer 5′-CCCT
AAACCTACCTTCCC-3′ for the RB1 assay. Pyrose-
quencing was performed using the PyroMark MD Q96
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Instrument (Pyrosequencing, Inc., Uppsala, Sweden) run-
ning PyroMark CpG software (version 1.0.9, Biotage GB
Ltd., Hengoed, UK). The plates were prepared for pyrose-
quencing according to the manufacturers’ protocol. Only
data which passed appropriate quality control thresholds
were included for analysis.
Statistical analysis
Data were analysed using STATA/SE version 13 (Stata
Corp, College Station, Texas, USA). Subject characteris-
tics of the entire cohort and pathological characteristics
of breast cancer cases were compared using Student’s t
test. Pairwise correlation was run to determine the rela-
tionship between CpG sites within each gene/region.
CpG sites within each gene (PEG3 and RB1; seven CpG
sites H19-ICR1, KvDMR-ICR2 and PLAGL1; six CpG
sites SNRPN and IGF2; four CpG sites each) were highly
correlated with each other (all at p < 0.01), and the aver-
age methylation for each of these genes/regions was
used in subsequent analysis. Linear regression was used
to determine the relationship between methylation and
age, weight, height and body mass index in the disease-
free control group.
Logistic regression was used to compare methylation
levels in the cases (IDC only, DCIS only and IDC and
DCIS combined) relative to the disease-free controls.
IDC was also compared with DCIS. Logistic regression
was used for other categorical outcomes (lymph node in-
volvement and receptor status). Multinomial logistic re-
gression was used to evaluate the link between
methylation and NPI categories. All analyses were ad-
justed for appropriate covariates including menopausal
status, age and weight (as stated in the tables and text).
The results of regression analysis are presented with
95 % confidence intervals and p values. Significance was
set at *p < 0.05, **p < 0.01 and ***p < 0.001. Due to the se-
vere effect of multiple comparison adjustments on false
negative error rates and the exploratory nature of this re-
search, such adjustments have been avoided to prevent this.
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